Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand"?) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand?s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand?s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.